G. Walmsley Graham Acquires 91,309 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) Director G. Walmsley Graham purchased 91,309 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average price of $44.75 per share, for a total transaction of $4,086,077.75. Following the purchase, the director now owns 1,091,309 shares in the company, valued at $48,836,077.75. This represents a 9.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

G. Walmsley Graham also recently made the following trade(s):

• On Thursday, March 27th, G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock. The stock was purchased at an average cost of $43.55 per share, with a total value of $2,177,500.00.
• On Thursday, January 30th, G. Walmsley Graham purchased 200,000 shares of Akero Therapeutics stock. The shares were purchased at an average cost of $48.00 per share, with a total value of $9,600,000.00.

Akero Therapeutics Trading Down 2.0 %

Akero Therapeutics stock opened at $42.72 on Friday. Akero Therapeutics, Inc. has a 12-month low of $17.86 and a 12-month high of $58.40. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -11.39 and a beta of -0.19. The firm has a 50 day moving average of $46.01 and a 200 day moving average of $35.02. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current year.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently bought and sold shares of AKRO. abrdn plc boosted its stake in shares of Akero Therapeutics by 118.7% in the fourth quarter. abrdn plc now owns 269,782 shares of the company’s stock worth $7,505,000 after acquiring an additional 146,424 shares during the period. FMR LLC boosted its stake in Akero Therapeutics by 732.1% in the 3rd quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after purchasing an additional 26,691 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Akero Therapeutics by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company’s stock valued at $15,042,000 after buying an additional 8,096 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Akero Therapeutics during the fourth quarter valued at approximately $320,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Akero Therapeutics by 4,022.1% in the fourth quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after buying an additional 583,486 shares in the last quarter.

Wall Street Analyst Weigh In

AKRO has been the topic of several recent analyst reports. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. UBS Group increased their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Finally, HC Wainwright boosted their target price on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $76.29.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.